Global Angina Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Angina Market Size

• The global Angina market size was valued at USD 14.23 billion in 2025 and is expected to reach USD 22.50 billion by 2033, at a CAGR of 5.90% during the forecast period
• The market growth is largely fueled by the rising prevalence of cardiovascular diseases, particularly coronary artery disease, along with increasing geriatric population and growing awareness regarding early diagnosis and treatment of angina conditions, leading to higher demand for effective therapeutic solutions
• Furthermore, advancements in pharmacological treatments, improved healthcare infrastructure, and increasing adoption of combination drug therapies are establishing angina treatment as a critical component of cardiovascular care. These converging factors are accelerating the adoption of angina therapeutics, thereby significantly boosting the industry's growth

Angina Market Analysis

• Angina, a clinical condition characterized by chest pain due to reduced blood flow to the heart, remains a critical focus area within cardiovascular care, with treatment approaches encompassing targeted drug classes and disease-specific management strategies aimed at reducing symptoms and preventing severe cardiac events
• The escalating demand for angina therapeutics is primarily fueled by the increasing global burden of cardiovascular diseases, growing aging population, and rising prevalence of risk factors such as hypertension, diabetes, obesity, and sedentary lifestyles
• North America dominated the angina market with the largest revenue share of 38.76% in 2025, characterized by advanced healthcare infrastructure, high awareness levels, and a strong presence of leading pharmaceutical companies, with the United States experiencing substantial growth in diagnosis and treatment rates driven by early screening programs and access to advanced drug therapies
• Asia-Pacific is expected to be the fastest growing region in the angina market during the forecast period due to increasing healthcare expenditure, rapid urbanization, and a growing patient pool affected by cardiovascular conditions
• Beta blockers segment dominated the angina market with a market share of 36.8% in 2025, driven by their widespread clinical use as first-line therapy for managing symptoms and reducing cardiac workload in patients with stable angina

Report Scope and Angina Market Segmentation       

Angina Market Trends

“Advancements in Combination Drug Therapies and Personalized Treatment Approaches”

• A significant and accelerating trend in the global angina market is the increasing adoption of combination drug therapies and personalized treatment approaches, aimed at improving patient outcomes and reducing the risk of severe cardiovascular events. This evolution in treatment strategies is significantly enhancing the effectiveness and precision of angina management
• For instance, combination therapies involving beta blockers and angiotensin-converting enzyme inhibitors are increasingly prescribed to manage symptoms while addressing underlying cardiovascular risk factors. Similarly, calcium channel blockers are often used alongside nitrates to improve blood flow and reduce chest pain frequency
• The integration of precision medicine in angina treatment enables tailored therapeutic approaches based on patient-specific risk profiles, genetic factors, and comorbid conditions. For instance, targeted drug regimens are being developed to optimize treatment outcomes in patients with microvascular angina and variant angina. Furthermore, improved diagnostic tools are allowing clinicians to identify specific angina types more accurately, leading to better treatment selection
• The seamless incorporation of advanced diagnostics and therapeutic strategies facilitates a more comprehensive approach to cardiovascular care. Through integrated care models, healthcare providers can manage angina alongside other chronic conditions such as hypertension and diabetes, creating a more coordinated and effective treatment framework
• This trend towards more precise, patient-centric, and outcome-driven treatment systems is fundamentally reshaping clinical practices in angina care. Consequently, companies such as Pfizer Inc. are focusing on developing advanced cardiovascular therapies that support combination treatment approaches and improved patient adherence
• The demand for advanced angina therapies that offer improved efficacy and personalized treatment options is growing rapidly across both developed and emerging healthcare markets, as patients and providers increasingly prioritize long-term cardiovascular health and quality of life
• The growing integration of digital health tools such as remote patient monitoring and wearable cardiac devices is supporting continuous assessment and timely intervention, thereby improving angina management efficiency

Angina Market Dynamics

Driver

“Rising Cardiovascular Disease Burden and Increasing Geriatric Population”

• The increasing global prevalence of cardiovascular diseases, along with a rapidly growing aging population, is a significant driver for the heightened demand for angina treatment solutions
• For instance, in March 2025, World Health Organization highlighted the continued rise in coronary artery disease cases globally, emphasizing the growing need for effective angina management strategies. Such developments are expected to drive the angina market growth in the forecast period
• As patients become more aware of cardiovascular health risks and seek timely medical intervention, angina treatments offer effective symptom control and prevention of complications, providing a critical component of cardiac care
• Furthermore, the expansion of healthcare infrastructure and improved access to diagnostic services are enabling earlier detection and treatment of angina, particularly in developing regions
• The availability of multiple drug classes such as beta blockers, nitrates, and ACE inhibitors, along with advancements in treatment protocols, is encouraging wider adoption of angina therapies in both hospital and outpatient settings. The increasing focus on preventive cardiology and chronic disease management further contributes to market growth
• The rising incidence of lifestyle-related disorders such as obesity and diabetes is further contributing to the growing patient pool requiring angina management solutions
• Increasing government initiatives and healthcare programs focused on cardiovascular disease prevention and management are supporting greater adoption of angina treatments across populations

Restraint/Challenge

“Side Effects of Long-Term Drug Use and High Treatment Costs”

• Concerns surrounding the side effects associated with long-term use of angina medications, including hypotension and dizziness, pose a significant challenge to broader treatment adoption
• For instance, clinical observations have indicated that prolonged use of nitrates and beta blockers can lead to tolerance development and reduced therapeutic effectiveness, making some patients hesitant to continue long-term therapy
• Addressing these concerns through improved drug formulations, optimized dosing strategies, and patient education is crucial for ensuring treatment adherence and effectiveness. Companies such as AstraZeneca plc are focusing on developing safer cardiovascular therapies with improved efficacy profiles. In addition, the relatively high cost of advanced treatment regimens and diagnostic procedures can be a barrier to access, particularly in low- and middle-income regions
• While healthcare access is improving globally, the financial burden associated with chronic cardiovascular treatment can still hinder consistent therapy adherence, especially among uninsured or underinsured populations
• Overcoming these challenges through cost-effective treatment options, enhanced healthcare coverage, and continuous innovation in drug development will be vital for sustaining growth in the angina market
• Limited awareness and underdiagnosis of certain angina types, particularly microvascular angina, can restrict timely treatment initiation and impact overall market growth
• Strict regulatory requirements and lengthy drug approval processes can delay the introduction of innovative therapies, thereby slowing market expansion

Angina Market Scope

The market is segmented on the basis of drug class, types, and end user.

• By Drug Class

On the basis of drug class, the angina market is segmented into beta blockers, nitrates and calcium channel blockers, angiotensin-converting enzyme inhibitors, and others. The beta blockers segment dominated the market with the largest market revenue share of 36.8% in 2025, driven by their widespread use as first-line therapy in managing angina symptoms and reducing myocardial oxygen demand. These drugs are extensively prescribed due to their proven efficacy in lowering heart rate and blood pressure, thereby minimizing the frequency and severity of angina attacks. In addition, beta blockers are well-established in clinical guidelines, further reinforcing their dominance in both developed and emerging healthcare systems. Their cost-effectiveness and availability as generic formulations also contribute to their high adoption rates across diverse patient populations. The growing burden of cardiovascular diseases continues to sustain demand for beta blockers globally.

The angiotensin-converting enzyme inhibitors segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by their increasing use in patients with comorbid conditions such as hypertension, diabetes, and heart failure. These drugs not only help in managing blood pressure but also provide protective effects on the heart and blood vessels, making them a preferred option in long-term cardiovascular care. Advancements in combination therapies and growing awareness of preventive cardiology are further accelerating their adoption. Moreover, their role in reducing the risk of adverse cardiac events is gaining recognition among healthcare providers. The expanding patient pool requiring integrated treatment approaches is expected to drive the growth of this segment.

• By Types

On the basis of types, the angina market is segmented into stable angina and unstable angina, variant (Prinzmetal) angina, and microvascular angina. The stable angina and unstable angina segment dominated the market with the largest market revenue share in 2025, driven by the high prevalence of coronary artery disease worldwide. Stable angina is the most commonly diagnosed form, characterized by predictable chest pain patterns, leading to consistent demand for long-term therapeutic management. Unstable angina, being a more severe and acute condition, often requires immediate medical intervention, further contributing to higher treatment volumes. The availability of well-established treatment protocols and widespread awareness among healthcare professionals supports the dominance of this segment. In addition, increasing screening and diagnostic rates are leading to early detection and continuous management of these conditions.

The microvascular angina segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing recognition and diagnosis of this previously underdiagnosed condition. Unlike traditional forms, microvascular angina affects the smaller coronary arteries, requiring specialized diagnostic approaches and tailored treatments. Growing advancements in imaging technologies and diagnostic techniques are improving detection rates, thereby driving demand for targeted therapies. Furthermore, increasing research into gender-specific cardiovascular conditions is highlighting the prevalence of microvascular angina, particularly among women. The need for personalized treatment strategies is expected to further accelerate growth in this segment.

• By End User

On the basis of end user, the angina market is segmented into hospitals, cardiology centers, and others. The hospitals segment dominated the market with the largest market revenue share in 2025, driven by the availability of advanced diagnostic equipment, specialized healthcare professionals, and comprehensive treatment facilities. Hospitals serve as primary centers for acute angina management, especially in emergency cases such as unstable angina, where immediate intervention is required. The presence of multidisciplinary care teams enables effective management of complex cardiovascular conditions. In addition, higher patient inflow and access to advanced therapeutic options contribute to the strong market position of hospitals. Government investments in healthcare infrastructure further support the dominance of this segment.

The cardiology centers segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing preference for specialized and outpatient cardiovascular care. These centers offer focused expertise, shorter waiting times, and cost-effective treatment options, making them an attractive choice for patients requiring ongoing angina management. The growing trend towards preventive cardiology and regular monitoring is further boosting demand for cardiology centers. Technological advancements in diagnostic and monitoring tools are enhancing their capabilities, enabling efficient patient care. The expansion of specialized clinics across emerging markets is expected to significantly contribute to the growth of this segment.

Angina Market Regional Analysis

• North America dominated the angina market with the largest revenue share of 38.76% in 2025, characterized by advanced healthcare infrastructure, high awareness levels, and a strong presence of leading pharmaceutical companies
• Patients in the region highly value the availability of advanced healthcare services, effective pharmacological treatments, and integrated care approaches offered by hospitals and cardiology centers for managing angina and associated cardiovascular conditions
• This widespread adoption is further supported by strong healthcare infrastructure, high healthcare expenditure, and a technologically advanced medical ecosystem, particularly in the United States, establishing angina treatment as a critical component of cardiovascular care across both inpatient and outpatient settings

U.S. Angina Market Insight

The U.S. angina market captured the largest revenue share of 81% in 2025 within North America, fueled by the high prevalence of cardiovascular diseases and the strong demand for advanced therapeutic solutions. Patients are increasingly prioritizing early diagnosis and effective management of angina through established drug therapies and specialized cardiac care. The growing preference for preventive cardiology, combined with robust access to healthcare services and innovative treatment options, further propels the angina market. Moreover, the increasing adoption of advanced diagnostic technologies and personalized treatment approaches is significantly contributing to the market's expansion.

Europe Angina Market Insight

The Europe angina market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising cardiovascular disease burden and increasing focus on preventive healthcare strategies. The increase in aging population, coupled with improved access to medical services, is fostering the adoption of angina treatments. European patients are also drawn to the availability of advanced therapies and structured healthcare systems. The region is experiencing significant growth across hospital and outpatient care settings, with angina management being integrated into broader cardiovascular treatment programs in both new and existing healthcare frameworks.

U.K. Angina Market Insight

The U.K. angina market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the increasing prevalence of heart-related conditions and a desire for improved patient outcomes and quality of life. In addition, concerns regarding cardiovascular health are encouraging both patients and healthcare providers to adopt early intervention and long-term treatment solutions. The U.K.’s strong healthcare system, alongside its emphasis on research and clinical innovation, is expected to continue to stimulate market growth.

Germany Angina Market Insight

The Germany angina market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of cardiovascular health and the demand for advanced and effective treatment solutions. Germany’s well-developed healthcare infrastructure, combined with its emphasis on innovation and high-quality care, promotes the adoption of angina therapies, particularly in hospitals and specialized cardiology centers. The integration of advanced diagnostic techniques and treatment protocols is also becoming increasingly prevalent, with a strong preference for efficient and patient-centric care aligning with local healthcare standards.

Asia-Pacific Angina Market Insight

The Asia-Pacific angina market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by increasing urbanization, rising healthcare expenditure, and the growing burden of cardiovascular diseases in countries such as China, Japan, and India. The region's growing focus on improving healthcare infrastructure, supported by government initiatives promoting better disease management, is driving the adoption of angina treatments. Furthermore, as Asia-Pacific emerges as a key region for pharmaceutical production and healthcare expansion, the accessibility and affordability of angina therapies are improving across a wider patient population.

Japan Angina Market Insight

The Japan angina market is gaining momentum due to the country’s aging population, advanced healthcare system, and increasing focus on cardiovascular disease management. The Japanese market places a significant emphasis on early diagnosis and effective treatment, and the adoption of angina therapies is driven by the rising number of patients with coronary conditions. The integration of advanced diagnostic tools and treatment protocols is fueling growth. Moreover, Japan's elderly population is likely to spur demand for long-term, efficient, and accessible angina treatment solutions in both hospital and outpatient settings.

India Angina Market Insight

The India angina market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country's rapidly growing population, increasing incidence of cardiovascular diseases, and expanding healthcare access. India stands as one of the fastest-growing markets for cardiovascular treatments, and angina therapies are becoming increasingly important across urban and rural healthcare settings. The push towards improved healthcare infrastructure and government-led health initiatives, alongside the availability of cost-effective generic medications, are key factors propelling the angina market in India.

Angina Market Share

The Angina industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• AstraZeneca U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• Sanofi (France)
• Bayer AG (Germany)
• GSK plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• AbbVie Inc. (U.S.)
• Amgen Inc. (U.S.)
• Abbott (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Limited (India)
• Astellas Pharma Inc. (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Dr. Reddy’s Laboratories Ltd. (India)

What are the Recent Developments in Global Angina Market?

• In September 2025, research published in Experimental Biology and Medicine highlighted the expanding therapeutic potential of ranolazine beyond its traditional antianginal use, including broader cardiovascular benefits through drug repurposing strategies. The study emphasized that such developments could enhance treatment efficacy and safety profiles, opening new avenues for innovation in angina management and related cardiovascular conditions
• In August 2025, clinical discussions and research publications emphasized the continued importance of ranolazine as an adjunct therapy for chronic angina, particularly in patients unresponsive to first-line treatments. The growing body of evidence supporting its efficacy in improving exercise tolerance and reducing angina episodes is strengthening its adoption in modern cardiovascular care
• In June 2025, a study published in Scientific Reports (Nature) demonstrated that ranolazine exhibits antioxidant properties that may contribute to improved cardiovascular outcomes in angina-related conditions. The research provided new in vivo evidence supporting its potential role beyond symptom control, highlighting its ability to enhance total antioxidant capacity. This development underscores ongoing innovation in angina therapeutics, particularly in exploring additional mechanisms to improve long-term patient outcomes
• In January 2025, a study published in Frontiers in Pharmacology evaluated the real-world safety profile of ranolazine, a widely used second-line therapy for chronic angina. The research highlighted important safety insights and reinforced the drug’s continued clinical relevance in patients with persistent angina symptoms despite standard treatments. This development supports ongoing optimization of angina drug therapy and long-term patient management strategies
• In March 2024, updated clinical and pharmacological reviews highlighted the expanding therapeutic potential of ranolazine beyond angina, including its antiarrhythmic benefits. These findings indicate broader cardiovascular applications, reinforcing innovation in angina-related drug development and combination therapy approaches

SKU-20426